Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations.
机构：[1]Department of Thoracic Oncology of Cancer Center, and Institute of Drug Clinical Trial, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu 610041, China四川大学华西医院[2]Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA[3]Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China四川大学华西医院[4]Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China四川大学华西医院
第一作者机构：[1]Department of Thoracic Oncology of Cancer Center, and Institute of Drug Clinical Trial, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu 610041, China
通讯作者：
推荐引用方式(GB/T 7714)：
Ning Liu,Min Yu,Tao Yin,et al.Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations.[J].Signal transduction and targeted therapy.2020,5(1):63.doi:10.1038/s41392-020-0161-7.
APA：
Ning Liu,Min Yu,Tao Yin,Yong Jiang,Xuelian Liao...&Yongsheng Wang.(2020).Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations..Signal transduction and targeted therapy,5,(1)
MLA：
Ning Liu,et al."Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations.".Signal transduction and targeted therapy 5..1(2020):63
医学